

# 台灣癌症登記中心通知

急件

發件人：台灣癌症登記中心  
電 話：02-2341-6012  
傳 真：02-2351-1733  
地 址：100 台北郵政 84-310 信箱  
日 期：106 年 1 月 6 日  
編 號：癌登第 106001 號

收文者：所有申報醫院

副本收文者：衛生福利部國民健康署、台灣癌症登記學會、資拓宏宇國際股份有限公司

主 題：因應106年癌症登記實務作業之需求，請 貴院依說明段辦理

急件       請檢閱       請加註       請回覆       請回收

- 
- 一、 本案係依衛生福利部國民健康署委託「台灣癌症登記工作計畫」辦理。
  - 二、「100 年版台灣癌症登記摘錄手冊」- 105 年修訂版及「癌症部位特定因子 (SSF) 編碼手冊」- 105 年修訂版，業由各醫院惠示意見並依據專家會議討論後修訂完竣，修訂版之附錄修訂處有詳細更新說明，提供醫院參考。完整修訂版檔案請逕至台灣癌症登記中心網站下載，網址如下：  
<http://tcr.cph.ntu.edu.tw/main.php?Page=A6>。
  - 三、 自 106 年起所有診斷年度個案，均全面採用上述 105 年修訂版申報。另 104 診斷年仍需申報個案，可沿用 104 年修訂版本申報，但必須於 106 年 3 月 3 日前依法完成申報。
  - 四、「100 年版台灣癌症登記摘錄手冊」與「癌症部位特定因子 (SSF) 編碼手冊」-105 年修訂版重要修正摘要如下，詳細內容請參考 105 年修訂版手冊：
    - (1) 修改分級/分化編碼優先順序。
    - (2) 治療狀態分類(癌登欄位序號#2.3.2)：新增編碼指引第五點說明，若攝護腺癌個案僅接受 TURP，後續醫生選擇積極監測(Active surveillance) 或予以密切觀察(Watchful waiting)時，應編碼為 4；且「首次療程開始日期」應摘錄決定積極監測或密切觀察的日期。
    - (3) 治療狀態分類(癌登欄位序號#2.3.2)：編碼指引第六點所敘述之 9950/3 Polycythemia vera，以及 9975/3 Myelodysplastic/myeloproliferative neoplasm, unclassifiable，已從其他治療項目移除。
    - (4) 其他分期系統(癌登欄位序號#3.17)：新增編碼 11 DRE (Digital rectal examination) Clinical T category 攝護腺癌的分期系統，為攝護腺癌個案必填欄位。
    - (5) 首次手術日期(癌登欄位序號#4.1.1)：新增編碼指引第一點，若攝護腺癌個案僅接受 TURP(術式編碼為 21-23)，「首次手術日期」及「原發部位最確切的手術切除日期」應編碼為 00000000；但必須於「原發部

位手術方式」摘錄術式。另若個案因 BPH 接受 TURP 後確診為攝護腺癌，後續接受 HIFU 治療；則「首次手術日期」及「原發部位最確切的手術切除日期」應編碼執行 HIFU 的日期，且「原發部位手術方式」編碼為 27。

- (6) 原發部位手術邊緣(癌登欄位序號#4.1.5)：新增編碼 C,D,E。
  - (7) 放射治療與手術順序(癌登欄位序號#4.2.1.5)、區域治療與全身性治療順序(癌登欄位序號#4.2.1.6)：若攝護腺癌個案僅接受 TURP(術式編碼為 21-23)時，不需比較治療順序。
  - (8) 體外放射治療技術(癌登欄位序號#4.2.2.1)：刪除編碼 16 質子療法。若個案僅接受質子治療時，需依據使用技術之不同來編碼為 1、2 或 4。
  - (9) 其他放射治療技術(癌登欄位序號#4.2.3.2)：刪除放術手術專用編碼 6 立體定位質子治療，另增修質子或其他帶電荷粒子治療專用編碼為 1、2、4、8、16、32、64、97、98、99。
  - (10) 摘錄者(癌登欄位序號#6.1)：摘錄此癌症登記個案人員之癌症登記證照編號，若無認證則摘錄姓名。
- 五、依據 SEER(2016)癌症登記編碼規則：自 105 診斷年起，Mature teratoma of the testes in adults 視為惡性須要申報，應編碼為 9080/3；若發生於青春期前的孩童，則依舊編碼為 9080/0 無須申報。
- 六、依據最新 WHO Classification of Tumours of the Urinary System and Male Genital Organs (2016)、WHO Classification of Tumours of the Central Nervous System (2016)彙整而成，因 2000 年出版之 ICD-O-3 編碼不敷使用，且現行病理報告按最新組織型態記載，故提供最新病理組織型態編碼供醫院使用（附件更新自癌登 105001 號通知文內容），注意事項如下：
- (1) Penis (C60) Warty carcinoma，從原本 M-code 8051/3 分離，新增編碼為 8054/3。
  - (2) 原 Kidney (C64.9) Clear cell papillary renal cell carcinoma 於 ICD-O-3 無編碼，依據 MP/H coding rules H6 描述當 Renal cell carcinoma, papillary and clear cell types 可編碼為 8255/**3** (Adenocarcinoma with mixed subtypes)，但因新版 WHO Classification of Tumours of the Urinary System and Male Genital Organs 新增 Clear cell papillary renal cell carcinoma 敘述，編碼為 8323/**1**，從惡性編碼變為良性編碼不需申報，請小心。
- 七、最新 AJCC Cancer Staging Manual 8th Edition 已於 2016 年底公布，將適用於 2018 年 1 月 1 日起新診斷之癌症個案，並於 2019 年(民國 108 年)起開始申報。有關 AJCC 第八版最新內容或勘誤表，請參閱以下網址：  
<https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx>

Status	ICD-O-3	Term
New term	8020/3	Poorly differentiated urothelial carcinoma (C65.9, C66.9, C67._, C68._)
New code and term	<b>8023/3</b>	<b>NUT carcinoma (C34._, C37.9)</b>
New term	8044/3	Small cell carcinoma, <b>hypercalcaemic type (C56.9)</b>
New code and term	<b>8054/3</b>	<b>Warty carcinoma (C60._) [originally 8051/3]</b>
New behavior code and term	8071/2	Differentiated-type vulvar intraepithelial neoplasia (C51._) Differentiated penile intraepithelial neoplasia (C60._)
New term	8077/2	<b>Penile intraepithelial neoplasia (C60._)</b>
New term	8144/3	Enteric adenocarcinoma (C34._)
New term	8200/3	<b>Thymic carcinoma with adenoid cystic carcinoma-like features (C37.9)</b>
New behavior code and term	<b>8250/2</b>	<b>Adenocarcinoma in situ, non-mucinous (C34._)</b>
New term	8250/3	<b>Lepidic adenocarcinoma (C34._)</b>
New behavior code and term	<b>8253/2</b>	<b>Adenocarcinoma in situ, mucinous (C34._)</b>
New term	8253/3	<b>Invasive mucinous adenocarcinoma (C34._)</b>
New term	8254/3	Mixed invasive mucinous and non-mucinous <b>adenocarcinoma (C34._)</b>
New code and term	<b>8256/3</b>	<b>Minimally invasive adenocarcinoma, non-mucinous (C34._)</b>
New code and term	<b>8257/3</b>	<b>Minimally invasive adenocarcinoma, mucinous (C34._)</b>
New code and term	<b>8311/3</b>	<b>Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma (C64.9)</b> <b>MiT family translocation renal cell carcinomas (C64.9)</b> <b>Succinate dehydrogenase-deficient renal carcinoma (C64.9)</b>
New term	8316/3	Acquired cystic disease-associated renal cell carcinoma (C64.9) <b>Tubulocystic renal cell carcinoma (C64.9)</b>
Behavior code change (3→1)	<b>8323/1</b>	<b>Clear cell papillary renal cell carcinoma (C64.9) [MP/H 8255/3→8323/1]</b>
New behavior code and term	8380/2	<b>Atypical hyperplasia / Endometrioid intraepithelial neoplasia (C54._)</b>
New behavior code and term	8441/2	<b>Serous tubal intraepithelial carcinoma (C57.0)</b>
New behavior code and term	8441/2	<b>Serous endometrial intraepithelial carcinoma (C54._)</b>
New behavior code and term	8460/2	<b>Serous borderline tumour - micropapillary variant (C56.9)</b>
New behavior code and term	8460/2	<b>Non-invasive low-grade serous carcinoma (C56.9)</b>

Status	ICD-O-3	Term
New term	8460/3	<b>Low-grade</b> serous carcinoma (C48._, C57._)
New term	8461/3	<b>High-grade</b> serous carcinoma (C48._, C57._)
New code and term	<b>8474/3</b>	<b>Seromucinous carcinoma (C56.9)</b>
New term	8480/3	Mucinous tubular and spindle cell carcinoma (C64.9)
New term	8500/3	<b>Adenocarcinoma of mammary gland type (C51._)</b>
New term	8504/2	<b>Encapsulated papillary carcinoma (C50._)</b>
New term	8504/3	<b>Encapsulated papillary carcinoma with invasion (C50._)</b>
New behavior code and term	8507/3	<b>Invasive micropapillary carcinoma (C50._)</b>
New code and term	<b>8509/2</b>	<b>Solid papillary carcinoma in situ (C50._)</b>
New code and term	<b>8509/3</b>	<b>Solid papillary carcinoma invasive (C50._)</b>
New term	8510/3	<b>Renal medullary carcinoma (C64.9)</b>
New code and term	<b>8519/2</b>	<b>Pleomorphic lobular carcinoma in situ (C50._)</b>
New term	8551/3	Acinar adenocarcinoma (C34._)
New term	8580/3	<b>Metaplastic thymoma / Sclerosing thymoma (C37.9)</b>
<b>Behavior code change (1→3)</b>	8581/3	<b>Type A thymoma, including atypical variant (C37.9)</b>
<b>Behavior code change (1→3)</b>	8582/3	<b>Type AB thymoma (C37.9)</b>
<b>Behavior code change (1→3)</b>	8583/3	<b>Type B1 thymoma (C37.9)</b>
<b>Behavior code change (1→3)</b>	8584/3	<b>Type B2 thymoma (C37.9)</b>
<b>Behavior code change (1→3)</b>	8585/3	<b>Type B3 thymoma (C37.9)</b>
New code and term	<b>8714/3</b>	Neoplasms with perivascular epithelioid cell differentiation (PEComa) NOS, malignant (C34._, C47._, C49._, C54._) Perivascular epithelioid cell tumour, malignant (C65.9, C66.9, C67._, C68._)
New term	8815/3	<b>Solitary fibrous tumor, grade 3 (C70._, C72._)</b>
New behavior code and term	8825/3	<b>Low-grade myofibroblastic sarcoma (C47._, C49._)</b>
<b>Behavior code change (3→1)</b>	<b>8832/1</b>	<b>Dermatofibrosarcoma protuberans (C47._, C49._)</b>
New term	8832/3	<b>Fibrosarcomatous dermatofibrosarcoma protuberans (C47._, C49._)</b>
<b>Behavior code change (3→1)</b>	<b>8833/1</b>	<b>Pigmented dermatofibrosarcoma protuberans (C47._, C49._)</b>
New term	8840/3	<b>Low-grade fibromyxoid sarcoma (C47._, C49._)</b> <b>Sclerosing epithelioid fibrosarcoma (C47._, C49._)</b>

Status	ICD-O-3	Term
New behavior code and term	8842/3	<b>Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation (C34._)</b> <b>Ossifying fibromyxoid tumour, malignant (C47._, C49._)</b>
New term	8936/3	<b>Extra-gastrointestinal stromal tumour (C48._)</b>
New term	8963/3	<b>Extra-renal rhabdoid tumour (C47._, C49._)</b>
New behavior code and term	8983/3	Adenomyoepithelioma <b>with carcinoma (C50._)</b>
New term	9084/3	<b>Germ cell tumours with somatic-type solid malignancy (C37.9)</b>
New code and term	<b>9086/3</b>	<b>Germ cell tumours with associated haematological malignancy (C37.9)</b>
New code and term	<b>9137/3</b>	<b>Pulmonary artery intimal sarcoma (C34._)</b> <b>Intimal sarcoma (C47._, C49._)</b>
New term	9180/3	<b>Extraskeletal osteosarcoma (C47._, C49._)</b>
New term	9231/3	<b>Extraskeletal myxoid chondrosarcoma (C47._, C49._)</b>
New code and term	<b>9385/3</b>	<b>Diffuse midline glioma, H3 K27M-mutant (C71._)</b>
New code and term	<b>9396/3</b>	<b>Ependymoma, RELA fusion-positive (C71._)</b>
New term	9424/3	<b>Anaplastic pleomorphic xanthoastrocytoma (C71._)</b>
New term	9440/3	Glioblastoma, <b>IDH-wildtype (C71._)</b>
New code and term	<b>9445/3</b>	<b>Glioblastoma, IDH-mutant (C71._)</b>
New term	9471/3	Medulloblastoma, <b>SHH-activated and TP53-wildtype (C71._)</b>
New term	9473/3	<b>CNS embryonal tumour, NOS (C71._)</b>
New code and term	<b>9475/3</b>	<b>Medulloblastoma, WNT-activated(C71._)</b>
New code and term	<b>9476/3</b>	<b>Medulloblastoma, SHH-activated and TP53-mutant (C71._)</b>
New code and term	<b>9477/3</b>	<b>Medulloblastoma, non-WNT/non-SHH (C71._)</b> <b>Medulloblastoma, group 3 / group 4 (C71._)</b>
New code and term	<b>9478/3</b>	<b>Embryonal tumour with multilayered rosettes, C19MC-altered (C71._)</b> <b>Embryonal tumour with multilayered rosettes, NOS (C71._)</b>
New term	9508/3	<b>CNS embryonal tumour with rhabdoid features (C71._)</b>
New term	9540/3	<b>MPNST with perineurial differentiation (C72._)</b>
New code and term	<b>9542/3</b>	<b>Epithelioid malignant peripheral nerve sheath tumour (C47._, C49._)</b>

說明：綠色網底表示為本次新增編碼與修訂敘述。